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doi:10.1016/j.jfma.2012.01.017Background/Purpose: Desflurane, with a low bloodegas partition coefficient, is an ideal anes-
thetic to achieve rapid offset and recovery from general anesthesia. Investigation of desflur-
ane elimination from blood and respiratory gas should provide useful information with
respect to a patient’s recovery from anesthesia. Therefore, this study is designed to charac-
terize the pharmacokinetics of desflurane elimination after cardiac surgery.
Methods: Sixteen patients undergoing coronary artery bypass graft surgery were enrolled.
At the end of surgery, multiple gas and blood samples were taken in the 20 minutes before
and after stopping desflurane administration, with prior maintenance of a fixed 7% inspired
desflurane in 6 L/minute oxygen flow for 60 minutes before the cessation. The blood desflur-
ane concentrations, including internal jugular-bulb blood (Jdes), arterial blood (Ades) and
pulmonary arterial blood (PAdes) were analyzed using gas chromatography. The inspiratory des-
flurane concentration (CIdes) and end-tidal desflurane (CEdes) were measured with an infrared
analyzer, and cardiac output was measured using an Opti-Q pulmonary artery catheter.
Results: Before cessation of desflurane administration, the inspiratory desflurane concentra-
tion (CIdes) was relatively higher than end-tidal (CEdes), arterial (Ades), internal jugular-bulb
blood (Jdes), and pulmonary (PAdes) concentrations in sequence (CIdes > CEdes > Adesy
Jdes > PAdes). During the elimination phase, rapid decay occurred in CEdes, followed by Jdes,t of Anesthesiology, Taipei Veterans General Hospital/National Defense Medical Center, 4F, Chung-
2, Shihpai Road, Beitou District, Taipei, Taiwan.
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186 C.-C. Lu et al.Ades and PAdes. Twenty minutes after stopping desflurane administration, the desflurane
concentrations were: PAdes > Adesy Jdes > CEdes. The decay curves of desflurane concentra-
tions demonstrated two distinct elimination components: an initial, fast 5-minute component
followed by a slow 15-minute component.
Conclusion: Desflurane is eliminated fastest from the lungs, as indicated by CEdes, compared to
elimination from circulating blood. The initial, rapid 5-minute desflurane washout reflected
the diluting effect of functional residual capacity of the lungs.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Desflurane has a lower rate of metabolism (0.02%), a low-
erbloodegas partition coefficient (0.42) and a lower
braineblood partition coefficient (1.29) compared with
other inhalational agents. These physical characteristics
make desflurane an ideal agent to achieve a rapid onset and
offset and hence faster induction and recovery from
general anesthesia.1 In clinical practice, inspired and end-
tidal concentrations are conventionally monitored by
a rapid gas analyzer during general anesthesia. Previous
studies found that the volatile anesthetic concentration (or
partial pressure) in end-tidal gas differs widely from that in
arterial blood,2-7 which has been considered to reflect more
accurately the concentration perfusing the brain and other
organs.8
Previous studies on the pharmacokinetics of isoflurane
elimination have reported different patterns of isoflurane
elimination from alveoli and blood, including arterial,
jugular venous and pulmonary arterial blood. However, still
no attempt has beenmade to quantify the pharmacokinetics
of desflurane elimination between blood and respiratory gas.
Therefore we have investigated the pharmacokinetics of
desflurane elimination during patient recovery from des-
flurane anesthesia.
Using gas chromatography (GC), the determination of
desflurane concentration in different circulating blood has
made possible the in vivo pharmacokinetic study of des-
flurane elimination from the brain and body.7 This study
was designed to characterize the eliminating kinetic
pattern of desflurane by simultaneous measurement of
circulating blood and respiratory gas in patients who had
undergone coronary artery bypass graft surgery.
Methods
Anesthetic procedure
The protocol was approved by the Institutional Review
Board (Tri-Service General Hospital, Taipei, Taiwan) and all
patients included in the study provided written informed
consent. Sixteen American Society of Anesthesiologists
(ASA) classification II or III patients for elective coronary
arterial bypass graft surgery under general anesthesia were
enrolled in this study.Premedications consisted of intrave-
nous fentanyl (2 mg/kg) and midazolam (40 mg/kg). Prior to
induction of anesthesia, a 20-gauge catheter was inserted
into the left radial artery for blood sampling under local
anesthesia. Blood pressure was continuously monitored.Anesthesia was induced with thiopental (3e4 mg/kg), and
intubation was facilitated with pretreatment with pan-
curonium (0.015 mg/kg) and succinylcholine (1.25 mg/kg).
A 7% inspired concentration of desflurane in 6 L/minute
oxygen flow was administered for 5 minutes to fill the anes-
thetic circuit and functional residual capacity, after which
the oxygen flow rate was reduced to 0.3 L/minute for main-
tenance of minimal low-flow anesthesia.9,10 Then, 5.5e7.5%
inspired desfluranewas adjusted tomaintain a hemodynamic
rangewithin 25%of baseline. After intubation, a single-lumen
central venous catheter and a pulmonary arterial catheter
were inserted into the right internal jugular-bulb and
pulmonary artery, respectively, for blood sampling, as
described previously.4-7,11 The cardiopulmonary bypass (CPB)
was set up for all patients with a crystalloid prime, a Med-
tronicmembraneoxygenator,moderatehypothermia (28 C),
hemodilution to a hematocrit of 20e25%, and alpha stat pH
management. A perfusionist administered 3.5e5.5% des-
flurane into the bypass circuit formaintenance of anesthesia.
After weaning from the CPB circuit, the patient was
ventilated again and the fresh gas oxygen flow rate was kept
at 0.3 L/minute, with 5.5e7.5% inspired desflurane before
the study of desflurane elimination was commenced (Fig. 1).
A Datex Aestiva/4 anesthetic machine (Datex, Helsinki,
Finland) was used with soda lime as CO2 absorber in the
breathing circuit. System leakage was determined using
constant-pressure ventilation with a test lung. All results
were corrected for the leakage specific to the given anes-
thetic machine. Anesthetic gas concentrations were moni-
tored on a multi-gas analyzer (Datex AS/4 Anesthesia
system; Datex, Helsinki, Finland) which had been cali-
brated according to the manufacturer’s recommendations.
Sampled gases (approximately 0.21 L/minute) were redir-
ected into the breathing circuit. The inspiratory desflurane
concentration (CIdes), end-tidal desflurane concentration
(CEdes), end-tidal CO2, blood pressure, and heart rate were
recorded every 30 seconds, and PaCO2 was maintained at
36e42 mmHg (4.8e5.6 kPa)during the study. A nasopha-
ryngeal thermistor was used to measure body temperature,
which was kept at 35.5e37.5C except for during the period
of CPB. Cardiac output was measured using an Opti-Q
catheter (Abbott Critical Care System, Mountain View, CA,
USA) and connected with a Q-Vue continuous cardiac
output computer during surgery.6,7,11 Hypotension, defined
as a 25% decrease in blood pressure from baseline, was
treated with intravenous fluid administration and/or
intravenous ephedrine (5 mg bolus). As reported in our
previous study,7 it takes 25 minutes to achieve equilibrium
between the arterial blood desflurane concentration (Ades)
and the internal jugular bulb desflurane concentration
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Figure 1 Schematic representation of time frame for coronary arterial bypass grafting surgery with cardiopulmonary bypass
under desflurane anesthesia. The sampling times for blood and gas phase desflurane concentrations were at e20, e10, 0 and 1, 3,
5, 10, 15 and 20 minutes after the cessation of desflurane administration. CIdes Z inspired desflurane concentration;
CPB Z cardiopulmonary bypass; FGF Z fresh gas flow; Induction Z start of anesthesia; C Z time point of blood sampling.
Desflurane elimination from human blood 187(Jdes). Therefore, a 6 L/minute constant oxygen flow was
maintained during the entire study (80 minutes), including
a 60-minute maintenance phase with a fixed 7% inspired
desflurane concentration prior to the completion of skin
closure and a 20-minute elimination phase after the
vaporizer was turned off (Fig. 1).
Collection of blood samples for desflurane
measurement
The sampling times for blood were at e20, e10, 0 (just
before), 1, 3, 5, 10, 15 and 20 minutes from the cessation of
the desflurane administration (Fig. 1). Arterial, jugular-
bulb and pulmonary artery blood samples were drawn
simultaneously from the respective indwelling catheters
into individual 1-mL heparinized syringes. The blood
samples from the internal jugular bulb were withdrawn
slowly at approximately 2 mL/minute to avoid contamina-
tion of internal jugular venous blood samples by blood
drainage from tissues other than the brain.12 Each 1-mL
blood sample was immediately injected into a 10-mL
tightly sealed glass vial, and stored in a refrigerator at
4C for measurement within 24 hours. All blood samples
were analyzed for desflurane concentration using a HP 6890
series GC system (Hewlett-Packard, Wilmington, DE, USA)
consisted of a headspace sampler, an oven, a flame-ioni-
zation detector according to the method used in our
previous study.7 Twenty-four hours after surgery all of the
patients were interviewed to determine the presence of
awareness during the desflurane elimination phase.
Determination of blood desflurane
concentration
Before determining the desflurane concentration in the
blood, 10 mL blood was obtained from each patient prior to
anesthesia as blank blood for determining the individual
bloodegas partition coefficient (l) of desflurane (Appendix
1). Desflurane in each blood sample was converted to thecorresponding concentration, based on gas chromatographic
measurements and individual bloodegas partition coeffi-
cient of desflurane (l) measured (Appendix 2).
Desflurane uptake and elimination
Under a fixed 7% inspired desflurane concentration, blood
desflurane concentration including Ades, Jdes and PAdes were
determined at e20, e10 and 0 minutes prior to the cessa-
tion of desflurane. Twenty minutes prior to stopping des-
flurane administration, the rate of desflurane body uptake
(mL of vapor per minute) was defined as follows: (Ades e
PAdes)Cardiac Output10. During the elimination phase,
the jugular bulb and pulmonary arterial blood provide
drainage from the brain and body, respectively. Therefore,
the decay of the Jdes time curve and PAdes time curve might
represent the desflurane elimination phases from the brain
and body, respectively. Desflurane concentration and
pharmacokinetic parameters were reported as mean 
standard deviation (SD).
Pharmacokinetic analysis
Pharmacokinetic analyses were performed for CEdes, Ades,
PAdes and PAdes time curves by using noncompartmental
methods with WinNonlin Professional version 5.2 (Pharsight
Corporation, Mountain View, CA, USA). The selection of the
best model was made by the Akaike information criterion
(AIC).13 The model that gives the lowest AIC value is
considered the best fit. The pharmacokinetic parameters,
including elimination half-life (t½), area under the
concentration time curve (AUC), and mean residence time
(MRT), were estimated from the model interpretation.
Statistical analysis
One-way analysis of variances (ANOVA) was conducted to
examine differences between the half-lives of four elimi-
nations with respect to parametric variables. The post-hoc
Table 2 Hemodynamic and ventilatory variables during
the 20 minutes before and after cessation of 7% inspired
desflurane (n Z 16).
Time
(min)
MABP
(mmHg)
HR
(beats/min)
CI
(L/min/m2)
ETCO2
(mmHg)
20 80.7 (13.9) 99.8 (10.6) 3.58 (1.10) 38.6 (2.8)
10 76.2 (12.6) 99.5 (12.7) 3.49 (1.07) 38.8 (3.3)
0 78.6 (10.2) 100.2 (11.9) 3.76 (1.30) 38.7 (3.2)
1 76.9 (12.2) 99.3 (13.2) 3.69 (1.20) 39.0 (3.1)
3 79.0 (10.3) 100.3 (12.3) 3.56 (1.28) 39.4 (3.3)
5 90.1 (11.6) 101.5 (13.6) 3.48 (1.15) 39.7 (3.0)
10 93.8 (12.2) 104.2 (13.8) 3.45 (1.21) 40.1 (3.0)
15 95.9 (12.5) 102.3 (13.7) 3.77 (1.37) 39.9 (3.3)
20 91.8 (13.7) 102.1 (13.7) 3.93 (1.54) 40.1 (3.0)
Values are presented as mean (SD).
CI Z cardiac index; ETCO2 Z end-tidal CO2; HR Z heart rate;
MABP Z mean arterial blood pressure.
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188 C.-C. Lu et al.Duncan test was conducted to test the significance of
parametric values. Data were expressed as mean (SD). A p
value <0.05 was regarded as statistically significant. A t
test was used to compare any of two desflurane concen-
trations between PAdes and Ades (or Jdes) 20 minutes after
the cessation of desflurane administration.
Results
Demographic data for the studypatients are shown in Table 1.
Patient hemodynamic and ventilatory parameters, including
mean arterial blood pressure, heart rate, cardiac index and
end-tidal CO2, are summarized in Table 2. They remained
stable throughout both the uptake and elimination phases of
the study. None of the patients reported awareness. The
mean (SD) of blood/gas partition coefficient of desflurane (l)
was 0.42 (0.02).
Fig. 2 depicts 7% inspired desflurane concentration
(CIdes), arterial (Ades), jugular-bulb (Jdes) and pulmonary
arterial desflurane (PAdes), and end-tidal desflurane
concentration (CEdes) in the 20 minutes prior to and after
the cessation of inspired desflurane. During the 20 minutes
prior to stopping desflurane administration,the CIdes was
relatively higher than CEdes, Ades, Jdes and PAdes (in
sequence). It shows that the concentrations of desflurane
(including CEdes, Ades, Jdes and PAdes) were nearly constant
during the 20-minute period before stopping desflurane
administration. At time 0 (just prior to the cessation of
desflurane), differentdesflurane concentrations were
observed in the following order: CIdes > CEdes > Ades
yJdes > PAdes. After stopping desflurane administration,
desflurane concentrationdecayed rapidly in CEdes, followed
by Ades (or Jdes) and then PAdes. The arterial desflurane
concentration was relatively lower than CEdes at time
0 (prior to cessation of desflurane) and the average ratio of
Ades:CEdes was 0.87. After 10, 15 and 20 minutes of the slow
elimination component, different ratios of Ades:CEdes were
listed as 2.32, 2.40 and 2.46, respectively. After 20 minutes
of desflurane elimination,PAdes was significantly higher than
Ades (p Z 0.02) and Jdes (p Z 0.03) (Tables 3 and 4).
We obtained the two-compartment model best fitted to
the concentration time curves of CEdes, Ades, PAdes and Jdes,
using the least squares method and Akaike’s information
criteria. After 5 minutes of elimination, the average des-
flurane concentrations of CEdes, Ades, Jdes and PAdes were
27%, 61%, 63% and 66% of their maximal concentration at
time 0. The distribution half-lives (i.e., the average timeTable 1 Patients’ demographic characteristics (n Z 16).
Age (y) 66 (12)
Weight (kg) 68 (12)
Height (cm) 163 (10)
Gender (M:F) 12:4
Duration of operation (min) 325 (42)
Duration of CPB (min) 113 (19)
Pancuronium consumption (mg) 10.4 (2.0)
Fentanyl consumption (mg) 255 (33)
Values are presented as mean (SD).
CPB Z cardiopulmonary bypass.for the desflurane concentration to reach 50% of its
maximal concentration) for CEdes, Ades, Jdes and PAdes were
0.5 (0.2), 2.4 (3.2), 3.8 (4.9) and 2.7 (3.3) minutes,
respectively.
There were no significant differences in alpha, beta,
distribution and elimination half-lives among CEdes, Ades,
Jdes and PAdes (Table 4). During the elimination phase, the
AUC (% min) for CEdes, Ades, Jdes and PAdes was 55.6 (10.6),
128.6 (32.3), 156.8 (71.8) and 165.8 (85.4), respectively.
The mean residence time (MRT) for CEdes, Ades, Jdes and
PAdes was 23.8 (6.8), 34.0 (13.6), 45.1 (32.9) and 45.9 (37.8)
minutes, respectively. There were no significant differ-
ences in AUC or MRT among CEdes, Ades, Jdes and PAdes.
Discussion
This is the first human study to simultaneously measure
desflurane concentrations in arterial blood, jugular-bulb-25 -20 -15 -10 -5 5 10 15 20 25
1.0
1.6
Time (min)
D
e
s
f
Figure 2 Desflurane concentration time curves during the 20
minutes before and after cessation of inspired desflurane
administration. The sampling times for blood and gas phase
desflurane concentrations were at e20, e10, 0 (before) and 1,
3, 5, 10, 15 and 20 minutes after the cessation of desflurane
administration. Desflurane concentrations of inspired (CIdes;
-A-), and end-tidal (CEdes; - -) gases, and arterial (Ades;
-:-), jugular-bulb (Jdes; -6-), and pulmonary arterial blood
(PAdes; ->-) are shown. Data are presented as mean (SD).
Table 3 CEdes, Ades, Jdes, PAdes and Ades:CEdes ratio under 7% inspired desflurane anesthesia at 0 minutes (just prior to
cessation of desflurane; as basal level of desflurane maintenance phase), and at 1, 3, 5, 10, 15 and 20 minutes after desflurane
discontinuation (n Z 16).
Time (min) 0 1 3 5 10 15 20
CEdes (%) 6.60 (0.18) 4.14 (1.81) 1.90 (0.45) 1.46 (0.31) 1.23 (0.20) 0.98 (0.16) 0.84 (0.14)
Ades (%) 5.75 (0.27) 4.77 (0.86) 3.97 (0.89) 3.49 (0.65) 2.72 (0.35) 2.29 (0.25) ** 2.01 (0.27) *
Jdes (%) 5.70 (0.53) 5.42 (0.84) 4.42 (0.55) 3.54 (0.54) 2.73 (0.35) 2.22 (0.27) ** 1.94 (0.24) *
PAdes (%) 5.47 (0.57) 4.87 (0.52) 4.19 (0.63) 3.63 (0.64) 2.86 (0.62) 2.55 (0.57) 2.23 (0.63)
Ades:CEdes 0.87 (0.05) 1.19 (0.63) 2.23 (0.81) 2.46 (0.53) 2.32 (0.42) 2.40 (0.51) 2.46 (0.60)
Values are mean (SD).
Ades Z desflurane concentration in arterial blood; CEdes Z end-tidal desflurane concentration; Jdes Z jugular-bulb blood desflurane
concentration; PAdes Z desflurane concentration in pulmonary arterial blood.
* p < 0.05.
** p < 0.01 vs. PAdes.
Desflurane elimination from human blood 189blood, pulmonary arterial blood and end-tidal gas during
the elimination phase. The study produced three main
findings. Firstly, there were two distinct components: an
initial 5-minute fast component and a subsequent 15-
minute slow elimination component for the above four
concentrationtime curves during desflurane elimination.
The decay of desflurane was rapid in end-tidal gas (CEdes),
followed by Jdes, Ades and PAdes. Secondly, under a fixed 7%
inspired desflurane concentration, the relationships
between different desflurane concentrations were:
CIdes > CEdes > Jdes y Ades > PAdes. Twenty minutes after
stopping desflurane administration, the desflurane
concentrations were: PAdes > Ades yJdes > CEdes. Thirdly,
the average Ades:CEdes ratio was 2.4 after 20 minutes of
elimination. The PAdes was relatively higher than both Jdes
and Ades after 20 minutes of elimination.
Yasuda et al. demonstrated that duration of desflurane
administration affects end-tidal desflurane (CEdes) elimi-
nation.2,8 In the present study, the average desflurane
exposure was 6.5 hours. CEdes0 denotesthe desflurane
concentration at time 0 (i.e., the last end-tidal desflurane
concentration during desflurane administration). The
gradient of the CEdes:CEdes0slope at 10e20 minutes of
elimination was about e0.0013, which was between the
values of 4 hours (e0.002) and 8 hours (e0.001) of des-
flurane exposure reported in previous study.14 Our study of
the rate of CEdes elimination was similar to the previous
study of Yasuda et al. In particular, the current study
illustrates pharmacokinetic analysis of blood desflurane
concentrations and provides the kinetic profile ofTable 4 The fitting of CEdes, Jdes, PAdes and Ades time curves w
Parameter a A B Alpha Beta
CEdes 10.23 (6.90) 1.80 (0.40) 1.47 (0.57) 0.039 (0.0
Ades 3.23 (2.39) 3.23 (0.98) 0.51 (0.32) 0.028 (0.0
Jdes 3.68 (1.80) 3.17 (0.83) 0.46 (0.54) 0.027 (0.0
PAdes 1.83 (1.11) 3.84 (1.09) 0.42 (0.33) 0.028 (0.0
Values are mean (SD).
Ades Z desflurane concentration in arterial blood; CEdes Z end-tida
concentration; PAdes Z desflurane concentration in pulmonary arteri
a Parameters of pharmacokinetic analysis of desflurane concentrat
desflurane) to 20 minutes. Bi-exponential equation: YZ A exp(ealphdesflurane elimination from circulating blood with respect
to patient recovery. These pharmacokinetic parameters of
desflurane elimination may provide useful correlation data
for future studies of pharmacodynamic responses during
emergence.
As is well known, desflurane is inhaled and absorbed
into body via alveoli.7 After cessation of desflurane
administration, the desflurane was washed out from the
brain and body via circulating blood, delivering it into the
alveolar space through the pulmonary arterial mixed
venous blood, and then allowing lungs to ventilate with
air. Simulating software was used to fit the time curves of
CEdes, Jdes, Ades and PAdes in a pharmacokinetic modelof
desflurane elimination and demonstrated a bi-exponential
curve. The average half-life during the fast elimination
component of the CEdes, Jdes, Ades and PAdestime curves
ranged from 0.5 to 3.4 minutes. Therefore, bi-
exponentially decaying functions were observed with
different time constants: an initial fast (less than
5 minutes) period and a subsequent slower elimination
component. This phenomenon suggested that the rapid
washout of desflurane from the function residual capacity
dominates the initial dilution of CEdes. With a character-
istic lower bloodegas partition coefficient (0.42), the Ades,
after alveolar exchange of desflurane, decreased rapidly,
which was followed by Jdes and PAdes. The effect of a large
gradient between pulmonary capillary and alveolar
concentration then disappeared after three time
constants of washout within 5 minutes at 6 L/minute
oxygen flow.15 Desflurane elimination appeared to becomeith bi-exponential equation (n Z 16).
Distribution half-life (min) Elimination half-life (min)
10) 0.5 (0.2) 19.1 (5.1)
17) 2.6 (3.2) 26.5 (11.0)
13) 3.8 (4.9) 27.4 (16.1)
19) 2.7 (3.3) 32.8 (27.6)
l desflurane concentration; Jdes Z jugular-bulb blood desflurane
al blood.
ion time curves were fitted from time 0 (just after cessation of
a T)þ B exp(ebeta T), where Y is CEdes, Ades, Jdes and PAdes.
190 C.-C. Lu et al.slower during the subsequent elimination component,
which might be explained by its relative higher
tissueeblood than that of gaseblood partition coefficient.
Our previous pharmacokinetic study of isoflurane elimi-
nation demonstrated two similar distinct components of
elimination for end-tidal and arterial blood isoflurane, but
there was only one component of isoflurane elimination for
pulmonary artery blood and jugular-bulb blood.11 This study
demonstrated that blood desflurane decays more rapidly
than isoflurane at the initial distribution component,
because both PAdes and Jdes were well fitted to the two-
component model. To explain why there was
bi-exponential decay of blood desflurane, but only mono-
exponential isoflurane elimination from pulmonary arterial
blood and jugular bulb blood, we suggest that desflurane
has a lower rate of metabolism, a lower bloodegas partition
coefficient and a lower braineblood partition coefficient
compared with isoflurane. Therefore, blood desflurane
decreases more rapidly because it passes from circulating
blood into the alveoli or tissue more rapidly than isoflurane.
Our study finding is consistent with the lesser solubility of
desflurane in blood and tissue,16 indicating that recovery
from anesthesia with desflurane will be more rapid than
from isoflurane in clinical practice.
There were no significant differences in the fast and
slow elimination half-lives of CEdes, Ades, Jdes and PAdes. The
decay rate of desflurane in gas (CEdes) was faster than those
in the blood (Ades, Jdes and PAdes) during the initial 5-minute
rapid component. The end-tidal desflurane concentration
(CEdes) descended rapidly and became the lowest concen-
tration than the others (Ades, Jdes and PAdes) during the
subsequent slow elimination component. It is interesting
that equations derived from the fitted curves ofAdes, Jdes
and PAdes might be used to estimate the desflurane
concentration of different circulating blood at certain
times during desflurane elimination. Perhaps, it will be
feasible to provide indicators for monitoring anesthetic
depth and also help theanesthesiologist predict more
precisely when a patient will be awakened from desflurane
anesthesia.17
There was a nearly constant relationship between
different desflurane concentrations, which was similar to
the previous study of desflurane uptake, in the following
order: CIdes > CEdes > Ades yJdes > PAdes.
7 The current
study also showed a similar pattern in desflurane concen-
trations just before the cessation of desflurane adminis-
tration. After stopping desflurane administration, the
decay of CEdes was rapid compared to blood desflurane. The
decrementing rate of blood desflurane was first in Ades,
second in Jdes, and last in PAdes. Then, 20 minutes after
stopping desflurane administration, the relationship
between desflurane concentrations was: PAdes > Ades
yJdes > CEdes. This phenomenon suggests that the elimi-
nation profile of desflurane in blood and gas could be
considered as the inverse of its uptake profile.
Our present study showed that the average ratios of
Ades:CEdes after 10, 15 and 20 minutes in the elimination
phase were 2.32, 2.40 and 2.46, respectively. Evidently,
CEdes does not always present the same ratio to Ades,
because it underestimates Ades during elimination.
However, the nearly constant Ades:CEdes ratios during the
slow component would reflect a first-order elimination ofdesflurane from circulating blood into alveolar space.
Perhaps, it would be possible to predict the desflurane
concentration in arterial blood from the end-tidal des-
flurane concentration, which could be measured using
noninvasive, rapid gas analyzers during emergence from
anesthesia.
There were two limitations in this study. First, the blood
sampling of desflurane was only achieved in a limited 20-
minute period following the cessation of desflurane. In
a typical elimination study, the samples of desflurane in
blood are often measured for a longer period to determine
the best fit for the concentration time curve. However we
stopped blood sampling 20 minutes after cessation of des-
flurane administration, because the patients’ anesthetic
depth became lighter and their respiratory patterns started
to become irregular. Second, the inspired desflurane
concentration had been adjusted according to the changes
of arterial blood pressure and heart rate during the pre-
bypass, bypass and post-bypass period, so the total body
uptake of desflurane could not be determined before
turning off the vaporizer. As such we could not derive the
volume distribution of desflurane during the elimination
phase.
In conclusion, the bi-exponential curve of desflurane
concentrations demonstrated two distinct components of
desflurane elimination. An initial rapid desflurane washout
caused by a functional residual capacity diluting effect
dominates the distribution component of desflurane elimi-
nation. Desflurane elimination from the lungs is the fastest,
indicated by CEdes, compared with the desflurane concen-
tration in circulating blood.Acknowledgments
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Determination of bloodegas partition coefficient
(l) of desflurane for each patient’s blood.
To obtain standard gas concentrations, five 550-mL glass
bottles, each with a turnable stopcock and Teflon septum
were used.18 After flushing each bottle with nitrogen for 6
minutes, the septum was pierced with a syringe needle and
2, 5, 10, 20, or 50 mL of liquid desflurane was injected into
the glass bottles at 4C. The calibration curve relating
counts to concentration was obtained by injecting different
concentrations of desflurane in 225 mL gas into the gas
chromatogram (GC) using a gas-tight Hamilton syringe
(Hamilton 250 mL; PN81156). The calculated desflurane
volume percentage was plotted against the measured GC
counts.
We used a similar method to that described by Smith
et al.19 to determine the bloodegas partition coefficient of
desflurane (l) as follows:
Desflurane elimination from human blood 1911. A 2-mL blood sample from each patient with known
desflurane concentration was added into the first
10-mL vial (with 2 mL of gas removed before
injection), sealed with a Teflon septum at 10C
temperature room and then incubated at 37C for 30
minutes.
2. The desflurane concentration in the headspace of the
first vial (C1) was determined by GC.
3. 1 mL of the sample was withdrawn immediately from
the first vial and transferred to a second 10-mL vial
(with 1 mL of gas removed before injection), sealed
with a Teflon septum and then incubated at 37C for
another 30 minutes.
4. The desflurane concentration in the headspace of the
second vial (C2) was again determined by GC. Thus, l
can be calculated by the following equation:
lZ
9C2
C1C2Appendix 2
Conversion of desflurane liquid to vapor by known
l of desflurane.
According to the physical properties of desflurane,
MW ⁄ D Z volume for 1 mole of desflurane liquid;
MW Z molecular weight (for desflurane, 168.04);
D Z density of desflurane, 1.4892 at 10C;
Standard bloodegas partition coefficient (desflu
rane) Z 0.42
According to the ideal gas law, 1 mole desflurane
(MW Z 168.04 g) is equal to 22.4 L of desflurane vapor at
1 atm pressure and 0C. Therefore, 1 mL desflurane
vapor Z 7.50 mg. As temperature is increased from 0 to
37C, 1 mL desflurane vapor should be equal to 6.61 mg,
according to the ideal gas law: V37CZ273K=273K þ 37K
7:50mg
The patient’s bloodegas partition coefficient obtained
in the above paragraph. For example, if lb/g is assumed to
be 0.42, an ideal equilibrated sample of 100 mL desflurane
gas and 100 mL of blood (each at 1% concentration) would
contain 6.61 mg and 2.8 mg of desflurane, respectively at
37C (1 atm). Therefore, it can be calculated that 1 mL of
1% desflurane in blood would contain 0.0281 mg of des-
flurane. In other words, the gas chromatogram (GC) count
measured from the headspace was registered as containing
1% of desflurane in blood, after 0.028 mg of desflurane was
injected into a 10-mL vial and equilibrated with 1 mL of
blank blood.
Gas chromatography conditions
The HP 6890 series GC system (Hewlett-Packard, Wilming-
ton, DE, USA) consisted of a headspace sampler (HP 7694 E),
an oven, a flame-ionization detector and an integrator. The
oven temperaturewas set at 40C, increased at a rate of 15C
per minute to 200C, and maintained at this level for 4.33
minutes. Both the injection and detection temperaturewere
set at 250C. An integrator and a data acquisition system
were provided by HP CHEMOSTATION software (Hewlett-
Packard, Wilmington, DE, USA).Calibration curve for measuring blood
desflurane concentration
A standard of liquid desflurane was equilibrated in a cold
bath at 10C for 1 hour before use. Five known amounts of
desflurane liquid were taken up using a microsyringe
(Hamilton 0.5 mL syringe; PN: 86259) and then injected into
five 10-mL glass vials (containing the patient’s 1-mL blank
blood). These vials were swirled in a cold bath at 10C for
30 minutes, and then transferred to a water bath at 37C for
30 minutes. A linear relationship between the signals for the
peak height of desflurane (y-axis) and desflurane concen-
tration (x-axis) was obtained and revealed an excellent
correlation with a range of 0.9975 and 0.9998 between the
signal and desflurane concentration. The analytical range of
the desflurane concentration was 0.70e17.5%. The des-
flurane concentration represented as the % could be con-
verted to the unit of partial pressure (mmHg) by the
following equation: 1 kPa Z 7.50 Torr (mmHg). Precision
and accuracy were determined on spiked human samples at
six concentrations (0.70e17.5%) with respect to a calibra-
tion graph prepared every day. The limit of detection (LOD)
was 0.02% per mL gas based on a signal-to-noise ratio of 3.
The limit of quantification (LOQ) of method for standard
samples was 0.1% per mL blood. The precision of the method
was expressed as the within-day and between-day coeffi-
cient of variation (%) less than 7.4%.
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